Digital Patient Support Program | Driving Adherence in India
Pharmaceutical and Medtech companies in India are moving beyond one-time product sales to digital patient support programs that extend patient relationships across the full treatment journey. These pharma-medtech collaborations are designed to improve adherence, generate repeat or lifecycle revenue, and create measurable value for patients, payers, and providers.
This brief outlines India’s opportunity for patient support program digital transformation, examines the prescription-to-program model, explores local enablers and barriers, and provides a framework for scalable, compliant, and outcome-driven growth across the patient lifecycle management continuum.
India’s Market Moment: Why the Window Is Open Now
India’s healthcare ecosystem is experiencing rapid digital acceleration, creating fertile ground for pharma digital partnerships and technology-led patient engagement.
-
Digital health expansion: India’s digital health market[1] was valued at US$14.50 billion in 2024 and is projected to reach US$106.97 billion by 2033, growing at a CAGR of 25.1%.
-
Adherence-program momentum: The India Patient Adherence Program market[2] reached US$235.6 million in 2023, forecast to hit US$894.8 million by 2030, growing at ~21% CAGR.
-
Persistent non-adherence: Nearly 50% of chronic-therapy patients[3] discontinue treatment within the first year, severely affecting health outcomes and long-term revenue.
-
Policy tailwinds: The World Economic Forum[4] recognizes India as a "global pathfinder in digital health," driven by the Ayushman Bharat Digital Mission (ABDM) and interoperable digital infrastructure.
Implication: The convergence of chronic disease growth, expanding digital reach, and policy momentum creates the perfect inflection point for pharma-medtech collaboration and digital patient support programs to capture value beyond the first prescription.
The Challenge: From Prescription to Continuous Engagement
For chronic conditions, commercial success now depends on sustained adherence and ongoing digital engagement that turns one-time users into lifelong patients.
-
Adherence decline: Globally, about 50% of patients stop therapy within the first year. Poor adherence leads to up to 37% lost pharma revenue, highlighting the need for medication adherence platforms and continuous support. (IQVIA[5])
-
Fragmented patient journeys: Lack of onboarding, digital literacy gaps, and non-integrated CRMs prevent meaningful intervention.
-
Transactional approach: The "sell and forget" model limits the potential of recurring engagement, device usage, or patient loyalty.
Without a connected pharma digital partnership framework, pharma and medtech firms cannot convert prescriptions into sustained, data-driven engagement programs. Collaboration is no longer optional; it is essential.
Why PSP Partnerships Are the New Growth Lever
Digital patient support programs (PSPs) combine technology, data, and human touch to transform patient engagement into measurable adherence and repeat revenue.
-
Reduced drop-offs: Evidence shows nurse-assisted, app-driven PSPs can improve adherence rates by up to 35%. (IQVIA)
-
Increased refills: Continuous loops through teleconsultations, remote monitoring, and localized nudges lift refill and renewal rates by 15 to 20%.
-
Connected ecosystems: Integration of wearables and analytics platforms enables pharma-medtech collaboration to collect real-world data for providers and payers.
PSPs transform the model from transactional sales to program-based relationships, driving patient lifecycle management and brand loyalty.
Pharma MedTech as the Growth Engine: Three Structural Shifts
a. From Molecule to Monitoring
Pharma contributes therapies and clinical expertise, while medtech offers connectivity, devices, and analytics. Together, they enable connected-care ecosystems where adherence and outcomes are tracked continuously.
b. From Transaction to Subscription
Digital patient support programs tied to devices enable recurring models such as remote monitoring subscriptions and digital coaching. Smart glucometers and inhalers in India demonstrate engagement rates three times higher than static programs.
c. From Product Data to Predictive Insights
Through medication adherence platforms, real-time analytics identify patients at risk of dropout, enabling automated interventions and data-backed clinical insights.
Major Pressure Points Holding Back Scale
1. Data silos and interoperability gaps
Around 60% of PSPs fail to move beyond basic enrolment metrics due to fragmented data systems. Next-gen PSPs must unify engagement, analytics, and marketing workflows.
2. Digital literacy and access
Semi-urban and rural populations face connectivity and usability challenges. PSPs must be mobile-first, vernacular, and low-bandwidth to scale effectively.
3. Regulatory and privacy concerns
Compliance with the Digital Personal Data Protection Act (2023) and ABDM interoperability standards is crucial for sustainable pharma digital partnerships.
Strategic Levers to Drive Sales Growth
1. Unified Digital Infrastructure
Implement a single patient support program digital platform that connects patients, providers, and field teams with real-time adherence dashboards. A leading insulin PSP in India reported a 28% rise in therapy continuation after integration.
For instance, technology enablers such as GrowthJockey are helping pharma and medtech companies unify PSP data streams through modular digital infrastructure from website and app development to AI-powered analytics using Intellsys AI, which measures marketing and engagement performance in real time to optimize patient acquisition and adherence campaigns.
2. Data-Driven Personalization
Use AI to predict non-adherence risk and deliver personalized nudges. Global benchmarks indicate that personalization increases retention by up to 22%.
3. Hybrid Human-Digital Engagement
Combine automation with human support through nurse helplines, WhatsApp communication, and telehealth check-ins to double adherence rates.
4. Commercial Integration
Tie PSP KPIs to core business metrics including renewal rates, upsell conversion, and device usage. Align incentive systems to adherence-driven growth.
5. Compliance and Trust
Adopt robust data governance, consent management, and ABDM-compatible interoperability. Compliance is now a competitive trust advantage in patient-centric healthcare.
Outlook and Implications for Leaders
Pharma–medtech collaborations around digital PSPs present a compelling route to transform initial prescriptions into sustained ecosystem engagements with measurable benefits: higher adherence, better outcomes, reduced waste, stronger brand loyalty and sustainable revenue streams.
-
The size and growth of digital health and adherence-support markets make this transition timely and commercially meaningful.
-
Firms that align early with India’s digital-health infrastructure (ABDM, EHRs) and design patient-centric, culturally localized programs will gain competitive advantage.
-
The revenue model is shifting: moving from “pill-sale” or “device-sale” to subscription, services, upgrades and data monetization.
-
Outcome-based contracting is becoming increasingly feasible as real-world data from PSPs mature, enabling payers and providers to reward better adherence and outcomes.
Path Forward
In India, converting prescriptions into programs is now the foundation of sustainable growth. Digital patient support programs powered by pharma-medtech collaboration enhance adherence, loyalty, and lifetime value.
With ABDM’s digital infrastructure maturing, companies that integrate PSPs into product launches and align incentives and data governance will outperform both clinically and commercially.
By partnering with technology enablers like GrowthJockey, organizations can accelerate this transition, building scalable, AI-driven, and compliant medication adherence platforms that convert every prescription into an ongoing program of care, driving the next wave of pharma digital partnership success in India.
Frequently Asked Questions (FAQs)
Q1. What is a digital patient support program?
Ans. It is a technology-enabled care model that helps patients stay on therapy through reminders, monitoring tools, and education, improving adherence and outcomes.
Q2. Why are pharma-MedTech collaborations important in India?
Ans. They combine pharma’s therapeutic expertise with medtech’s digital capabilities to build connected care ecosystems that enhance patient engagement and retention.
Q3. How do digital PSPs improve medication adherence?
Ans. By using apps, remote monitoring, and AI-driven nudges, digital PSPs reduce therapy drop-offs and increase refill rates, strengthening long-term adherence.
Q4. What role do pharma digital partnerships play in sales growth?
Ans. They help convert one-time prescriptions into ongoing programs, driving repeat revenue and better patient lifecycle management through data analytics and personalization.
Q5. What is the future of medication adherence platforms in India?
Ans. With digital health and ABDM expanding, India’s PSP market is set for rapid growth, making AI-driven, patient-centric platforms a core engine for healthcare innovation and revenue.
Industries
Growth
Operations
Technology